Citigroup
FBRX

Citigroup’s Forte Biosciences FBRX Stock Holding History

Citigroup’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$193K Buy
+9,102
New +$216K ﹤0.01% 4361
2026
Q1 		– Sell
-1,279
Closed -$34.9K – 6087
2025
Q4 		$34.9K Buy
+1,279
New +$22.4K ﹤0.01% 4698
2022
Q3 		– Sell
-5
Closed – – 5976
2022
Q2 		$0 Sell
5
-20
-80% -$635 ﹤0.01% 6353
2022
Q1 		$1K Sell
25
-76
-75% -$2.88K ﹤0.01% 6161
2021
Q4 		$5K Buy
101
+48
+91% +$3.23K ﹤0.01% 5657
2021
Q3 		$4K Buy
53
+28
+112% +$15.5K ﹤0.01% 5607
2021
Q2 		$21K Sell
25
-262
-91% -$236K ﹤0.01% 5269
2021
Q1 		$246K Hold
287
– – ﹤0.01% 3909
2020
Q4 		$261K Buy
287
+282
+5,640% +$265K ﹤0.01% 4780
2020
Q3 		$6K Sell
5
-2
-29% -$1.33K ﹤0.01% 6893
2020
Q2 		$2K Sell
7
-13
-65% -$5.81K ﹤0.01% 7404
2020
Q1 		$9K Buy
20
+4
+25% +$1.56K ﹤0.01% 7075
2019
Q4 		$3K Sell
16
-8
-33% -$1.81K ﹤0.01% 7492
2019
Q3 		$6K Sell
24
-13
-35% -$19.7K ﹤0.01% 7269
2019
Q2 		$92K Sell
37
-5
-12% -$14.8K ﹤0.01% 5951
2019
Q1 		$172K Sell
42
-1,177
-97% -$4.55M ﹤0.01% 5246
2018
Q4 		$3.75M Buy
1,219
+1,159
+1,932% +$4.99M ﹤0.01% 2087
2018
Q3 		$354K Buy
+60
New +$228K ﹤0.01% 4671
2018
Q2 		– Sell
-6
Closed -$28K – 7636
2018
Q1 		$28K Sell
6
-1
-14% -$4.63K ﹤0.01% 6546
2017
Q4 		$26K Buy
+7
New +$27.9K ﹤0.01% 6589
2017
Q3 		– Hold
0
– -$1K – 7294
2017
Q2 		– Hold
0
– – – 7141

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Citigroup's FBRX Position: Q2 2026 in Review

Citigroup opened a new position in Forte Biosciences (FBRX) in Q2 2026: 9,102 shares worth $193K. The stake represents ﹤0.01% of the portfolio and ranks #4361 among its holdings. This is a return to the name: Citigroup previously reported a position in FBRX as recently as Q4 2025.

Citigroup first reported a position in FBRX in Q4 2017 and has held it in 20 quarters since. The position peaked at $3.75M in Q4 2018. 86 funds tracked by Wall St. Rank hold FBRX as of Q2 2026.

  • Citigroup held 9,102 shares of Forte Biosciences worth $193K as of Q2 2026.
  • Forte Biosciences was a new Citigroup position in Q2 2026.
  • Forte Biosciences made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4361 holding.
  • Citigroup first reported a position in Forte Biosciences in Q4 2017 and has held it in 20 quarters since.
  • Citigroup's Forte Biosciences position peaked at $3.75M in Q4 2018.
  • 86 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.